Cancer Profile (CA Profile)
The Cancer Profile, or CA Profile to which it is commonly referred, is a lab panel developed by Dr. Emil K. Schandl of American Metabolic Laboratories in Hollywood, FL. This test requires both blood and urine specimens, and measures several markers thought to be associated with and/or elevated in cancer. These include phosphohexose isomerase (PHI) enzyme, human chorionic gonadotropin (HCG), and carcinoembryonic antigen (CEA), as well as thyroid stimulating hormone (TSH), DHEA-S, and GGTP.
Phosphohexose Isomerase (PHI) is an enzyme that plays a role in regulating anaerobic metabolism (i.e., a cell’s energy production in the absence of oxygen). This enzyme is also referred to as the Autocrine Motility Factor (AMF), and is thought to be one of the main causes of malignancy. Dr. Schandl’s research suggests that PHI plays a significant role in cells becoming cancerous. However, PHI is not exclusively a cancer marker. Although the PHI level can be elevated in cancerous conditions, it can also go up with viral illnesses, liver disease, and heart disease.
Human chorionic gonadotropin (HCG) is known as the pregnancy hormone, since it is elevated during pregnancy and is the basis for pregnancy tests. However, Dr. Schandl refers to it as the malignancy hormone since it can be used as a broad-spectrum tumor marker. Research has found that HCG is elevated in 70-80% of all cancers. On the Cancer Profile test, it is evaluated in both blood and urine. There are other labs which evaluate HCG, but only in urine, and with inferior technology.
Carcinoembryonic antigen (CEA) is a conventional tumor marker which can be elevated in various cancer types.
In Dr. Schandl’s research, these three cancer markers (PHI, HCG, and CEA) were elevated in 92% of breast cancer cases, 93% of colon cancer patients, and 92% of lung cancer cases. By including several other lab tests as part of the CA Profile, he believes that the accuracy is improved.
As is the case with other alternative lab tests, the CA Profile is not part of the standard of care, and is not diagnostic. However, it can be helpful in monitoring the cancer burden in the body as well as the patient’s response to treatment, as well as for long-term monitoring when cancer is “in remission.”